Health & Science
Dr. Mari Mitrani of OrganiCell on Stem Cell Research, Exosomes, and Regenerative Medicine
Dr. Mari Mitrani, Chief Science Officer of OrganiCell, explains what stem cells actually are, why perinatal-source stem cells and exosomes represent the cutting edge of regenerative medicine, and why none of it requires embryonic or animal testing.
Topics Covered
- Dr. Mitrani's upbringing in Ecuador by two physician parents who practiced whole-food, plant-based medicine decades before it was mainstream
- What a stem cell is: an undifferentiated 'master cell' capable of becoming any specialized tissue in the body
- The early years of autologous (patient's-own) stem cell therapy, including bone marrow and blood-derived collection methods
- Why embryonic stem cells are controversial and carry teratoma risk, and how perinatal-source stem cells from planned, fully-screened C-section donations avoid that issue entirely
- Exosomes explained: the newly understood cell-to-cell communication vesicles now used for both diagnosis and treatment
- Current clinical research into osteoarthritis of the knee, cardiology, and pulmonology applications
- Why no animal testing is used in her company's autologous and perinatal stem cell research
About the Guest
Dr. Mari Mitrani is Chief Science Officer of OrganiCell, a regenerative medicine company researching stem cell and exosome therapies for orthopedic, cardiac, and pulmonary conditions. She was raised in Ecuador in a family of physicians who practiced whole-food, plant-based and natural medicine, and has spent over a decade at the forefront of stem cell and exosome research.